CIK 0001806310 · Non-accelerated filer<br>Smaller reporting company
Taysha Gene Therapies, Inc.
Sign in to watch- Ticker
- TSHA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 843199512
- Phone
- (214) 612-0000
- Business address
- 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX, 75247
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 7 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-08-24 | Alam Kamran Chief Financial Officer | Sale 10b5-1 | −33,000 | $2.33 | $77K | 258,042 |
| 2023-08-16 | Manning Paul B 10% owner | Purchase | +16,466,667 | $0.90 | $14.8M | 16,466,667 |
| 2023-08-16 | Stalfort John A III Director | Purchase | +388,889 | $0.90 | $350K | 884,290 |
| 2023-08-16 | Stalfort John A III Director | Purchase | +388,889 | $0.90 | $350K | 999,381 |
| 2023-08-16 | Stalfort John A III Director | Gift | +50,000 | 1,049,381 | ||
| 2023-08-16 | Nolan Sean P. Chief Executive Officer | Purchase | +444,444 | $0.90 | $400K | 1,535,545 |
| 2023-08-16 | Donenberg Phillip B. Director | Purchase | +111,111 | $0.90 | $100K | 114,111 |
| 2023-07-13 | Session R.A. II 10% owner | Sale | −5,344 | $0.70 | $4K | 8,871,747 |
| 2023-07-12 | Session R.A. II 10% owner | Sale | −80,528 | $0.71 | $57K | 8,877,091 |
| 2023-06-23 | Session R.A. II 10% owner | Sale | −18,100 | $0.70 | $13K | 8,957,619 |
| 2023-06-22 | Sepp-Lorenzino Laura Director | Grant or award · Stock Option (right to buy) | +36,200 | 36,200 | ||
| 2023-06-22 | Reape Kathleen Director | Grant or award · Stock Option (right to buy) | +36,200 | 36,200 | ||
| 2023-06-22 | Donenberg Phillip B. Director | Grant or award · Stock Option (right to buy) | +36,200 | 36,200 | ||
| 2023-06-22 | Stalfort John A III Director | Grant or award · Stock Option (right to buy) | +43,800 | 43,800 | ||
| 2023-06-22 | Session R.A. II 10% owner | Sale | −10,508 | $0.70 | $7K | 8,975,719 |
| 2023-06-21 | Session R.A. II 10% owner | Sale | −138,962 | $0.70 | $98K | 8,986,227 |
| 2023-06-20 | Session R.A. II 10% owner | Sale | −295,653 | $0.71 | $210K | 9,125,189 |
| 2023-05-31 | Alam Kamran CHIEF FINANCIAL OFFICER | Grant or award · Employee Stock Option (right to buy) | +12,462 | 12,462 | ||
| 2023-05-31 | Alam Kamran Chief Financial Officer | Grant or award | +6,230 | 291,042 | ||
| 2023-05-16 | Nagendran Sukumar President and Head of R&D | Purchase | +5,000 | $0.68 | $3K | 34,226 |
Page 5 of 9 · 173 trades